STOCK TITAN

Envoy Medical Expands Intellectual Property Portfolio to 99 Patents with New U.S. and Hong Kong Patent Grants

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Envoy Medical (COCH) received two additional patents in the United States and Hong Kong, bringing its global portfolio to 99 granted patents.

U.S. Patent No. 12,773,553 covers cochlear implant electrode impedance diagnostics, including adjusting prescribed current based on voltage differences. Hong Kong Patent No. HK40105814 covers external-device analysis and display of signals from a fully implantable cochlear implant system. The portfolio comprises 41 U.S. and 58 foreign granted patents, with 32 applications pending: 24 foreign and eight U.S.

Loading...
Loading translation...

Positive

  • Minor pointU.S. Patent No. 12,773,553 adds protection for cochlear implant electrode impedance diagnostics.
  • Minor pointHong Kong Patent No. HK40105814 adds protection for integrated cochlear implant signal analysis.

Negative

  • None.

Key Figures

Additional patents granted: 2 patents Granted patent portfolio: 99 patents Pending applications: 32 applications
Additional patents granted
2 patents
United States and Hong Kong
Granted patent portfolio
99 patents
Global total
Pending applications
32 applications
24 foreign and 8 U.S.

Key Terms

electrode impedance, compliance voltage, pivotal clinical trial, breakthrough device designation
4 terms
electrode impedance technical
"Cochlear Implant Electrode Impedance Diagnostics"
Electrical opposition presented by an electrode and its immediate environment to an applied alternating current; it combines resistance and reactance and is measured in ohms. Electrode impedance reflects the electrode material, surface area, the condition of the interface (for example tissue contact, fluid layers or insulation integrity) and the test frequency and waveform, so reported values depend on how and when the measurement was made. Clinically and in device testing it is used as an objective metric of connection quality and the electrical load seen by sensing or stimulation circuits, but it does not by itself identify the specific cause of a high or low reading.
compliance voltage technical
"the compliance voltage associated with applying that current"
Compliance voltage is the maximum electrical pressure a medical device or regulated current source can produce while still delivering a steady, intended current; think of it as the highest water pressure a pump can use while keeping flow rate constant. For investors, it matters because it affects a device’s ability to reach and safely stimulate target tissue, influences battery life and component costs, and can be a factor in regulatory approval and market competitiveness.
pivotal clinical trial medical
"under investigation as part of a U.S.-based pivotal clinical trial"
A pivotal clinical trial is a late-stage medical study designed to provide the main evidence regulators use to decide whether a drug or medical device can be approved and sold; think of it as the product’s final exam. For investors, the trial’s outcome is critical because a clear pass can unlock regulatory approval, market access and future revenue, while failure can halt commercialization and materially affect a company’s valuation.
breakthrough device designation regulatory
"received the Breakthrough Device Designation from the U.S. Food and Drug Administration"
A breakthrough device designation is a regulatory program that gives promising medical devices for serious or life‑threatening conditions priority support and faster review from a health authority (e.g., the U.S. FDA). Think of it as a “fast lane” or VIP pass through development and review: it can shorten time to market, lower regulatory uncertainty, and boost a company’s commercial prospects — but it is not an approval by itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

New Patents Cover Cochlear Implant Electrode Impedance Diagnostics and Integrated Signal Analysis Functionality

White Bear Lake, Minnesota--(Newsfile Corp. - November 17, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced it has been granted two additional patents in the United States and Hong Kong, bringing its intellectual property portfolio to 99 patents. In addition, the Company has 24 pending foreign applications and eight pending U.S. applications, further expanding its intellectual property portfolio.

The United States Patent and Trademark Office granted U.S. Patent No. 12,773,553 to Envoy Medical, titled "Cochlear Implant System with Electrode Impedance Diagnostics." The patent covers stimulation path impedance and compliance voltages in cochlear implant systems. It describes a system that can adjust a prescribed current when the compliance voltage associated with applying that current differs sufficiently from an applied compliance voltage.

The Hong Kong Patent Office granted Hong Kong Patent No. HK40105814 to Envoy Medical, titled "Cochlear Implant System with Integrated Signal Analysis Functionality." The patent covers using an external device to indicate a signal within a fully implantable cochlear implant system for analysis, receiving a representative signal from the system, and outputting a representation of that signal.

Expanding Global Intellectual Property Portfolio

Envoy Medical's intellectual property portfolio spans different technologies and ideas supporting current developments as well as future improvements of its fully implanted hearing platform technologies, including sensing, signal processing, implantation and system integration.

Envoy Medical's global patent portfolio now consists of:

  • 41 U.S. granted patents

  • 58 foreign granted patents

  • 99 total granted patents globally

  • 32 pending applications (24 foreign and 8 U.S.)

The foreign patent count includes, for granted European cases, the European Patent ("EP") separately from and in addition to corresponding individual country validations and unitary patents.

To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.

About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health and neuroprosthetics company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.

The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.

The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.

The Acclaim CI is currently under investigation as part of a U.S.-based pivotal clinical trial. For more information on the trial, visit www.envoymedical.com/acclaim-pivotal.

CAUTION: The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.

*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.

Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.

Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the ability to obtain additional patents and develop future products or product improvements; the Acclaim CI being the first to market fully implanted cochlear implant; the timing, content, and results of the Company's modular PMA submissions to the FDA, including the number and timing of modules and the timing of any approval decision; the timing and results of approvals, site documents, logistics, activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, including data from Stage 2 (which may differ from Stage 1); the results of the safety and efficacy data from Stage 2 participants and the effect on its pooling with Stage 1 data; performance of the Acclaim CI during clinical trials, including improvement of patient outcomes over time after implant; and the participation or any changes in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; changes in reimbursement for the Esteem FI-AMEI device or other changes in reimbursement policies or coverage decisions, changes in the hearing health market, and further development of the Esteem FI-AMEI device; the sufficiency of the Company's capital resources; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 23, 2026, and in other reports Envoy Medical files with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.

Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324403

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many granted patents does Envoy Medical have after its latest patent grants?

Envoy Medical has 99 granted patents globally following the additional U.S. and Hong Kong grants. The portfolio consists of 41 U.S. granted patents and 58 foreign granted patents.

How does Envoy Medical count European patents in its foreign patent portfolio?

Envoy Medical counts granted European Patents separately from their corresponding individual country validations and unitary patents. These entries are included in its foreign granted patent count.

Keep reading